Emerging nanomedicine opportunities with perfluorocarbon nanoparticles

Perfluorocarbon (PFC) nanoparticles can serve as a platform technology for molecular imaging and targeted drug-delivery applications. These nanoparticles are approximately 250 nm in diameter and are encapsulated in a phospholipid shell, which provides an ideal surface for the incorporation of targeting ligands, imaging agents and drugs. For molecular imaging, PFC nanoparticles can carry very large payloads of gadolinium to detect pathological biomarkers with magnetic resonance imaging. A variety of different epitopes, including αvβ3-integrin, tissue factor and fibrin, have been imaged using nanoparticles formulated with appropriate antibodies or peptidomimentics as targeting ligands. Lipophilic drugs can also be incorporated into the outer lipid shell of nanoparticles for targeted delivery. Upon binding to the target cell, the drug is exchanged from the particle surfactant monolayer to the cell membrane through a novel process called ‘contact facilitated drug delivery’. By combining targeted molecular imaging and localized drug delivery, PFC nanoparticles provide diagnosis and therapy with a single agent.

[1]  T. Mekhail,et al.  Paclitaxel in cancer therapy , 2002, Expert opinion on pharmacotherapy.

[2]  S. Flaim Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[3]  D. Curiel,et al.  Cellular vehicles for cancer gene therapy: current status and future potential. , 2004, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[4]  Andreas Saleh,et al.  In vivo MRI of brain in ̄ ammation in human ischaemic stroke , 2004 .

[5]  Samuel A Wickline,et al.  Targeted ultrasonic contrast agents for molecular imaging and therapy. , 2001, Current problems in cardiology.

[6]  Bartley P. Griffith,et al.  Macrophage Accumulation Associated With Rat Cardiac Allograft Rejection Detected by Magnetic Resonance Imaging With Ultrasmall Superparamagnetic Iron Oxide Particles , 2001, Circulation.

[7]  M. Brechbiel,et al.  3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties , 2001, Magnetic resonance in medicine.

[8]  T. Lüscher,et al.  Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications , 2006, Circulation.

[9]  Mair Zamir,et al.  Functional anatomy and hemodynamic characteristics of vasa vasorum in the walls of porcine coronary arteries. , 2003, The anatomical record. Part A, Discoveries in molecular, cellular, and evolutionary biology.

[10]  Samuel A Wickline,et al.  Targeted contrast agents for magnetic resonance imaging and ultrasound. , 2005, Current opinion in biotechnology.

[11]  R E Jacobs,et al.  Magnetic resonance microscopy of embryonic cell lineages and movements. , 1994, Science.

[12]  S. Caruthers,et al.  1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. , 2005, Current topics in developmental biology.

[13]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[14]  Patrick Winter,et al.  Applications of Nanotechnology to Atherosclerosis, Thrombosis, and Vascular Biology , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[15]  J. Debatin,et al.  Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.

[16]  Ergin Atalar,et al.  In Vivo Magnetic Resonance Imaging of Mesenchymal Stem Cells in Myocardial Infarction , 2003, Circulation.

[17]  Chien Ho,et al.  Intracellular labeling of T‐cells with superparamagnetic contrast agents , 1993, Magnetic resonance in medicine.

[18]  J. G. Miller,et al.  A novel site-targeted ultrasonic contrast agent with broad biomedical application. , 1996, Circulation.

[19]  R. Mattrey The potential role of perfluorochemicals (PFCs) in diagnostic imaging. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.

[20]  Shelton D Caruthers,et al.  Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy , 2005, Expert review of cardiovascular therapy.

[21]  M. Daemen,et al.  Atherosclerotic plaque rupture: local or systemic process? , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Sheng-Kwei Song,et al.  High‐resolution MRI characterization of human thrombus using a novel fibrin‐targeted paramagnetic nanoparticle contrast agent , 2000, Magnetic resonance in medicine.

[23]  K. Peters,et al.  Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. , 1998, American heart journal.

[24]  S. Caruthers,et al.  Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. , 2004, Current pharmaceutical biotechnology.

[25]  A. Sinusas,et al.  Detection of Injury-Induced Vascular Remodeling by Targeting Activated &agr;vβ3 Integrin In Vivo , 2004 .

[26]  P. Winter,et al.  Improved Paramagnetic Chelate for Molecular Imaging with MRI , 2005 .

[27]  Shelton D Caruthers,et al.  Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI , 2004, Magnetic resonance in medicine.

[28]  Shelton D Caruthers,et al.  Targeted magnetic resonance imaging contrast agents. , 2006, Methods in molecular medicine.

[29]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[30]  L. Naldini,et al.  Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. , 2006, Biochimica et biophysica acta.

[31]  E T Ahrens,et al.  Receptor‐mediated endocytosis of iron‐oxide particles provides efficient labeling of dendritic cells for in vivo MR imaging , 2003, Magnetic resonance in medicine.

[32]  Qingbo Xu,et al.  The molecular mechanisms of vascular restenosis: Which genes are crucial? , 2006, Current vascular pharmacology.

[33]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[34]  Shelton D Caruthers,et al.  In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.

[35]  Scott E. Fraser,et al.  Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study , 2004, NeuroImage.

[36]  M. Bock,et al.  High‐resolution three‐dimensional MR angiography of rodent tumors: Morphologic characterization of intratumoral vasculature , 2003, Journal of magnetic resonance imaging : JMRI.

[37]  S A Wickline,et al.  Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. , 2000, Investigative radiology.

[38]  M. Brechbiel,et al.  Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores , 2001, Magnetic resonance in medicine.

[39]  David A. Cheresh,et al.  Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging , 1998, Nature Medicine.

[40]  Samuel A Wickline,et al.  Nanotechnology for molecular imaging and targeted therapy. , 2003, Circulation.

[41]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. V. Role of acute distension in the induction of smooth muscle proliferation. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[42]  S. Robinson,et al.  Design, synthesis, and evaluation of radiolabeled integrin αvβ3 receptor antagonists for tumor imaging and radiotherapy , 2003 .

[43]  Shelton D Caruthers,et al.  Molecular imaging of human thrombus with computed tomography. , 2005, Academic radiology.

[44]  Samuel A Wickline,et al.  Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound contrast agent for molecular imaging. , 2005, The Journal of the Acoustical Society of America.

[45]  T J Brady,et al.  Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. , 1992, Radiology.

[46]  Juan J. Badimon,et al.  Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta: Implications for Plaque Vulnerability , 2004, Circulation.

[47]  R. Müller,et al.  Nanostructured lipid matrices for improved microencapsulation of drugs. , 2002, International journal of pharmaceutics.

[48]  S. Fazel,et al.  Current status of cellular therapy for ischemic heart disease. , 2005, The Annals of thoracic surgery.

[49]  Samuel A Wickline,et al.  Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. , 2005, Ultrasound in medicine & biology.

[50]  E. Wu,et al.  Mapping cyclic change of regional myocardial blood volume using steady‐state susceptibility effect of iron oxide nanoparticles , 2004, Journal of magnetic resonance imaging : JMRI.

[51]  Eric T Ahrens,et al.  In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.

[52]  D. Agrawal,et al.  In stent restenosis: bane of the stent era , 2006, Journal of Clinical Pathology.

[53]  R. Virmani,et al.  Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel , 2002, Circulation.

[54]  Samuel A Wickline,et al.  Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.

[55]  M. Naghavi,et al.  Superparamagnetic Iron Oxide–Based Method for Quantifying Recruitment of Monocytes to Mouse Atherosclerotic Lesions In Vivo: Enhancement by Tissue Necrosis Factor-&agr;, Interleukin-1&bgr;, and Interferon-&ggr; , 2003, Circulation.

[56]  Samuel A Wickline,et al.  Molecular imaging, targeted therapeutics, and nanoscience , 2002, Journal of cellular biochemistry. Supplement.

[57]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[58]  H. Verheul,et al.  Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. , 2006, Current pharmaceutical design.

[59]  S. Caruthers,et al.  Molecular imaging by MRI , 2006, Current cardiology reports.

[60]  Grace Hu,et al.  Molecular MR imaging of melanoma angiogenesis with ανβ3‐targeted paramagnetic nanoparticles , 2005, Magnetic resonance in medicine.

[61]  A. C. van der Wal,et al.  Tissue factor expression in the morphologic spectrum of vulnerable atherosclerotic plaques. , 2006, Seminars in thrombosis and hemostasis.

[62]  K. Moulton Plaque angiogenesis: its functions and regulation. , 2002, Cold Spring Harbor symposia on quantitative biology.

[63]  F. Khuri,et al.  Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  Stasia A. Anderson,et al.  Magnetic resonance contrast enhancement of neovasculature with αvβ3‐targeted nanoparticles , 2000 .

[65]  Patrick J. Gaffney,et al.  Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .

[66]  N. Ferrara,et al.  Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia , 2004, Circulation.

[67]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[68]  J. Werkmeister,et al.  MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. , 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[69]  J. Frank,et al.  Cellular magnetic resonance imaging: current status and future prospects , 2006, Expert review of medical devices.

[70]  J. G. Miller,et al.  In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[71]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[72]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[73]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[74]  S M Schwartz,et al.  Angiogenesis in human coronary atherosclerotic plaques. , 1994, The American journal of pathology.

[75]  Shelton D Caruthers,et al.  Magnetic resonance molecular imaging with nanoparticles , 2004, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[76]  Samuel A. Wickline,et al.  Endothelial &agr;&ngr;&bgr;3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis , 2006 .

[77]  Sheng-Kwei Song,et al.  Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.